Novavax had been hoping to find a sizable sales opportunity by advancing a protein-based alternative to the messenger RNA ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated ...

On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Also Read: DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable ... Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

However, production of the mRNA used in vaccines is hindered by its ... New mRNA Vaccine Created to Prevent and Treat C. Difficile Oct. 17, 2024 — A new vaccine provides hope for treating and ...

[emphasis in original] Yee cited by name Moderna (NASDAQ: MRNA) as an example of a vaccine developer hurt by declining ...

The Wyandotte woman had worked at Blue Cross for 32 years and was denied a religious accommodation to the insurer's vaccine ...